Estrogen and progesterone receptors in some human myeloma cell lines and murine hybridomas.

The control of immune responses by sex hormones is well documented but the effect of sex hormones on lymphoid cell subsets is poorly understood. We have investigated the expression of receptors for androgens (AR), estradiol (ER) and progesterone (PR) by human cell lines of the B lymphocyte lineage and by murine myeloma or hybridomas. AR, ER and PR were determined by cytosol and nuclear binding assays.

Distribution of androgen and estrogen receptors among lymphoid and haemopoietic cell lines.

Estrogen receptors (ER) and androgen receptors (AR) were determined in a series of 23 leukemia or lymphoma cell lines including 8 T-cell lines, 12 B-cell lines, and 3 non lymphoid cell lines. The phenotypic characterization of these cells by currently available immunological markers provides an estimate of their stage of differentiation. The result indicate that none of the investigated cell lines bear simultaneously ER and AR.

Characterization of a specific androgen receptor in non-Hodgkin's lymphoma cells.

The use of a competitive binding assay has permitted us to detect a cytoplasmic androgen receptor in cells of node biopsies of several patients suffering from non-Hodgkin's malignant lymphomas (NHML). These same cells appear to contain very low or undetectable numbers of estrogen receptor. The androgen receptors are saturated at approximately 2 X 10(-10) M [3H] 5 alpha DHT and Scatchard analyses of the binding data indicated a high affinity constant (Kd = 0.

Sex steroid receptors in peripheral T cells: absence of androgen receptors and restriction of estrogen receptors to OKT8-positive cells.

The immune response has been reported to be modulated by sex hormones in several models, and estrogen receptors have been demonstrated in the human thymus. We therefore investigated the presence of estrogen and androgen receptors among human peripheral T cells; thoracic duct lymph provided large amounts of circulating lymphocytes. Pure T cells were obtained by negative selection by using complement-dependent cytotoxicity with a monoclonal antibody against a monomorphic determinant of class II histocompatibility antigen (HLA-DR).